Stand Up To Cancer Awards $5.5 Million for Epigenetic Immunotherapy Trials – AJMC.com Managed Markets Network
|
Stand Up To Cancer Awards $5.5 Million for Epigenetic Immunotherapy Trials
AJMC.com Managed Markets Network While many lung and bladder cancer patients respond well to immunotherapy, they eventually succumb to the disease because the immune system can not detect the cancer cells. Two clinical trials will combine immunotherapy with epigenetic agents in order … |
